Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Ma CX, et al. Among authors: bedard pl. Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679771 Free PMC article. Clinical Trial.
Luminal-B breast cancer and novel therapeutic targets.
Tran B, Bedard PL. Tran B, et al. Among authors: bedard pl. Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22217398 Free PMC article. Review.
Management of small HER2 overexpressing tumours.
Templeton A, Ocaña A, Seruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Templeton A, et al. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9. Epub 2012 Sep 6. Breast Cancer Res Treat. 2012. PMID: 22956007
Personalized medicine for metastatic breast cancer.
Chen TW, Bedard PL. Chen TW, et al. Among authors: bedard pl. Curr Opin Oncol. 2013 Nov;25(6):615-24. doi: 10.1097/CCO.0000000000000015. Curr Opin Oncol. 2013. PMID: 24097103 Review.
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C. Bedard PL, et al. Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10. Clin Cancer Res. 2015. PMID: 25500057 Clinical Trial.
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Vera-Badillo FE, et al. Among authors: bedard pl. J Clin Pathol. 2015 Oct;68(10):839-43. doi: 10.1136/jclinpath-2015-203012. Epub 2015 Jun 15. J Clin Pathol. 2015. PMID: 26076967
255 results